Abstract | BACKGROUND: METHODS: The menstrual diaries of 134 post-menopausal women who completed a dose-ranging study of trimegestone and then entered a 6 month extension phase were analysed. In the 6 month extension study, all women were given one dose of trimegestone (0.25 mg) in a sequential fashion (day 15-28) combined with continuous E(2) (2 mg/day). RESULTS: Women who had received trimegestone 0.25 mg/day during the first 6 months experienced no change in the bleeding pattern in the 6 month extension. Women who had been treated with 0.5 mg/day dose experienced earlier onset, and more prolonged bleeding (P < 0.0001) following the change to 0.25 mg/day. Women who previously received trimegestone doses of 0.05 and 0.1 mg experienced a later onset of bleeding, which was lighter and of shorter duration (P < 0.001) during the extension phase as compared with the first 6 months. CONCLUSION:
|
Authors | May Wahab, John Thompson, Malcolm Whitehead, Farook Al-Azzawi |
Journal | Human reproduction (Oxford, England)
(Hum Reprod)
Vol. 17
Issue 5
Pg. 1386-90
(May 2002)
ISSN: 0268-1161 [Print] England |
PMID | 11980769
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Progestins
- trimegestone
- Promegestone
|
Topics |
- Dose-Response Relationship, Drug
- Endometrium
(pathology)
- Estrogen Replacement Therapy
(adverse effects)
- Female
- Humans
- Incidence
- Medical Records
- Middle Aged
- Progestins
(adverse effects)
- Promegestone
(administration & dosage, analogs & derivatives, therapeutic use)
- Severity of Illness Index
- Time Factors
- Uterine Hemorrhage
(chemically induced, drug therapy, epidemiology, physiopathology)
|